|
| 33935020 | Implications of Guideline-based, Risk-stratified Restaging Transurethral Resection of High-grade Ta Urothelial Carcinoma on Bacillus Calmette-Guérin Therapy Outcomes. | Eur Urol Oncol | 2022 |
| 35770498 | All High-Grade Ta Tumors Should Be Classified as High Risk: Bacillus Calmette-Guérin Response in High-Grade Ta Tumors. | J Urol | 2022 |
| 35770497 | Reply by Authors. | J Urol | 2022 |
| 33210440 | The obesity paradox: defining the impact of body mass index and diabetes mellitus for patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin. | BJU Int | 2021 |
| 33484074 | Impact of upper tract urothelial carcinoma on response to BCG in patients with non-muscle-invasive bladder cancer. | BJU Int | 2021 |
| 33734859 | Reply by Authors. | J Urol | 2021 |
| 33783950 | Time interval from transurethral resection of bladder tumour to bacille Calmette-Guérin induction does not impact therapeutic response. | BJU Int | 2021 |
| 30301695 | Prognostic Implication of the United States Food and Drug Administration-defined BCG-unresponsive Disease. | Eur Urol | 2019 |
| 30105454 | Epidemiology, prevention, screening, diagnosis, and evaluation: update of the ICUD-SIU joint consultation on bladder cancer. | World J Urol | 2019 |
| 31200843 | Using Grade of Recurrent Tumor to Guide Further Therapy While on Bacillus Calmette-Guerin: Low-grade Recurrences Are not Benign. | Eur Urol Oncol | 2019 |
| 31279815 | Can Biomarkers Guide the Use of Neoadjuvant Chemotherapy in T2 Bladder Cancer? | Eur Urol Oncol | 2019 |
| 30784602 | Whole-Organ Genomic Characterization of Mucosal Field Effects Initiating Bladder Carcinogenesis. | Cell Rep | 2019 |
| 29529165 | Is folic acid safe for non-muscle-invasive bladder cancer patients? An evidence-based cohort study. | Am J Clin Nutr | 2018 |
| 27753185 | Clinical risk stratification in patients with surgically resectable micropapillary bladder cancer. | BJU Int | 2017 |
| 28263732 | Editorial Comment. | J Urol | 2017 |
| 26119560 | Cytokine Panel for Response to Intravesical Therapy (CyPRIT): Nomogram of Changes in Urinary Cytokine Levels Predicts Patient Response to Bacillus Calmette-Guérin. | Eur Urol | 2016 |
| 27641313 | Microhematuria assessment an IBCN consensus-Based upon a critical review of current guidelines. | Urol Oncol | 2016 |
| 27782819 | Erratum to: The UBC-40 Urothelial Bladder Cancer cell line index: a genomic resource for functional studies. | BMC Genomics | 2016 |
| 27428265 | Innovation in Bladder Cancer Immunotherapy. | J Immunother | 2016 |
| 27387678 | Phase 1b Trial to Evaluate Tissue Response to a Second Dose of Intravesical Recombinant Adenoviral Interferon α2b Formulated in Syn3 for Failures of Bacillus Calmette-Guerin (BCG) Therapy in Nonmuscle Invasive Bladder Cancer. | Ann Surg Oncol | 2016 |
| 27376146 | The Impact of Blue Light Cystoscopy with Hexaminolevulinate (HAL) on Progression of Bladder Cancer - A New Analysis. | Bladder Cancer | 2016 |
| 27368880 | Follow-up in non-muscle-invasive bladder cancer-International Bladder Cancer Network recommendations. | Urol Oncol | 2016 |
| 26922408 | Papillary Recurrence of Bladder Cancer at First Evaluation after Induction Bacillus Calmette-Guérin Therapy: Implication for Clinical Trial Design. | Eur Urol | 2016 |
| 25254936 | Clinical outcomes of cT1 micropapillary bladder cancer. | J Urol | 2015 |
| 26621286 | Erratum to: The UBC-40 Urothelial Bladder Cancer Cell Line Index: a genomic resource for functional studies. | BMC Genomics | 2015 |
| 25997541 | The UBC-40 Urothelial Bladder Cancer cell line index: a genomic resource for functional studies. | BMC Genomics | 2015 |
| 25800393 | Expert consensus document: Consensus statement on best practice management regarding the use of intravesical immunotherapy with BCG for bladder cancer. | Nat Rev Urol | 2015 |
| 23911605 | Refining patient selection for neoadjuvant chemotherapy before radical cystectomy. | J Urol | 2014 |
| 25245244 | Hexaminolevulinate blue-light cystoscopy in non-muscle-invasive bladder cancer: review of the clinical evidence and consensus statement on appropriate use in the USA. | Nat Rev Urol | 2014 |
| 25320178 | The 19q12 bladder cancer GWAS signal: association with cyclin E function and aggressive disease. | Cancer Res | 2014 |
| 25027329 | Imputation and subset-based association analysis across different cancer types identifies multiple independent risk loci in the TERT-CLPTM1L region on chromosome 5p15.33. | Hum Mol Genet | 2014 |
| 25174656 | Intravesical tumor involvement of the trigone is associated with nodal metastasis in patients undergoing radical cystectomy. | Urology | 2014 |
| 24768021 | Anterior fascial fixation does not reduce the parastomal hernia rate after radical cystectomy and ileal conduit. | Urology | 2014 |
| 24768020 | Reply: To PMID 24768009. | Urology | 2014 |
| 24768013 | Safety of hexaminolevulinate for blue light cystoscopy in bladder cancer. A combined analysis of the trials used for registration and postmarketing data. | Urology | 2014 |
| 24411790 | Considerations on the use of urine markers in the management of patients with low-/intermediate-risk non-muscle invasive bladder cancer. | Urol Oncol | 2014 |
| 24053608 | Clinical significance of ureteric 'skip lesions' at the time of radical cystectomy: the M.D. Anderson experience and literature review. | BJU Int | 2014 |
| 22564397 | Neoadjuvant chemotherapy in small cell urothelial cancer improves pathologic downstaging and long-term outcomes: results from a retrospective study at the MD Anderson Cancer Center. | Eur Urol | 2013 |
| 24456786 | Delayed ureterectomy after incomplete nephroureterectomy for upper tract urothelial carcinoma: pathologic findings and outcomes. | Int Braz J Urol | 2013 |
| 23602406 | Photodynamic diagnosis of non-muscle-invasive bladder cancer with hexaminolevulinate cystoscopy: a meta-analysis of detection and recurrence based on raw data. | Eur Urol | 2013 |
| 23507396 | Phase I trial of intravesical recombinant adenovirus mediated interferon-α2b formulated in Syn3 for Bacillus Calmette-Guérin failures in nonmuscle invasive bladder cancer. | J Urol | 2013 |
| 23313034 | Screening for bladder cancer: rationale, limitations, whom to target, and perspectives. | Eur Urol | 2013 |
| 22914978 | A phase 2 clinical trial of sequential neoadjuvant chemotherapy with ifosfamide, doxorubicin, and gemcitabine followed by cisplatin, gemcitabine, and ifosfamide in locally advanced urothelial cancer: final results. | Cancer | 2013 |
| 22877502 | Epidemiology and risk factors of urothelial bladder cancer. | Eur Urol | 2013 |
| 21396845 | The role of FISH and cytology in upper urinary tract surveillance after radical cystectomy for bladder cancer. | Urol Oncol | 2012 |
| 23218068 | Practical use of perioperative chemotherapy for muscle-invasive bladder cancer: summary of session at the Society of Urologic Oncology annual meeting. | Urol Oncol | 2012 |
| 22701660 | Association of polymorphisms in oxidative stress genes with clinical outcomes for bladder cancer treated with Bacillus Calmette-Guérin. | PLoS One | 2012 |
| 22758775 | Lymph node density for patient counselling about prognosis and for designing clinical trials of adjuvant therapies after radical cystectomy. | BJU Int | 2012 |
| 22879988 | Detection of bladder cancer using proteomic profiling of urine sediments. | PLoS One | 2012 |
| 22583635 | Long-term decrease in bladder cancer recurrence with hexaminolevulinate enabled fluorescence cystoscopy. | J Urol | 2012 |